Just days after UK pharmaceutical firm AstraZeneca rejected a $119 billion acquisition bid, Pfizer says it will no longer pursue the acquisition, ending the chances of a new top industry player of emerging.
Pfizer announced Monday it would no longer pursue AstraZeneca and would not consider a hostile takeover bid. Under …read more
Source: Global Competition Law Blogs